NM_000077.5(CDKN2A):c.190C>G (p.Leu64Val) AND Familial melanoma

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Oct 28, 2022
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV003746687.2

Allele description [Variation Report for NM_000077.5(CDKN2A):c.190C>G (p.Leu64Val)]

NM_000077.5(CDKN2A):c.190C>G (p.Leu64Val)

Gene:

CDKN2A:cyclin dependent kinase inhibitor 2A [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

9p21.3

Genomic location:

Preferred name:

NM_000077.5(CDKN2A):c.190C>G (p.Leu64Val)

HGVS:

NC_000009.12:g.21971169G>C
NG_007485.1:g.28323C>G
NM_000077.5:c.190C>GMANE SELECT
NM_001195132.2:c.190C>G
NM_001363763.2:c.37C>G
NM_058195.4:c.233C>G
NM_058197.5:c.*113C>G
NP_000068.1:p.Leu64Val
NP_000068.1:p.Leu64Val
NP_001182061.1:p.Leu64Val
NP_001350692.1:p.Leu13Val
NP_478102.2:p.Ala78Gly
NP_478102.2:p.Ala78Gly
LRG_11t1:c.190C>G
LRG_11t2:c.233C>G
LRG_11:g.28323C>G
LRG_11p1:p.Leu64Val
LRG_11p2:p.Ala78Gly
NC_000009.11:g.21971168G>C
NM_000077.4:c.190C>G
NM_058195.3:c.233C>G

Protein change:

A78G

Molecular consequence:

NM_058197.5:c.*113C>G - 3 prime UTR variant - [Sequence Ontology: SO:0001624]
NM_000077.5:c.190C>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001195132.2:c.190C>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001363763.2:c.37C>G - missense variant - [Sequence Ontology: SO:0001583]
NM_058195.4:c.233C>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:: Familial melanoma
Synonyms:: Hereditary melanoma; Hereditary cutaneous melanoma
Identifiers:: MONDO: MONDO:0018961; MedGen: C1512419

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV004412812	Labcorp Genetics (formerly Invitae), Labcorp	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015))	Uncertain significance (Oct 28, 2022)	germline	clinical testing	PubMed (1) [See all records that cite this PMID]

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV004412812

Labcorp Genetics (formerly Invitae), Labcorp

criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))

Uncertain significance
(Oct 28, 2022)

germline

clinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]

PMID:: 28492532
PMCID:: PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV004412812.1

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (1)

Description

In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. This variant is also known as c.233C>G (p.Ala78Gly) in CDKN2A (p14ARF) transcript. This variant has not been reported in the literature in individuals affected with CDKN2A (p16INK4a)-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 64 of the CDKN2A (p16INK4a) protein (p.Leu64Val).

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Sep 29, 2024

ClinVar

Relating variation to medicine